October 2015

Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Conditions:   Hodgkin's Lymphoma;   Lymphoid Leukemia;   Lymphoma;   Leukemia;   Myeloma
Interventions:   Drug: mycophenolate mofetil;   Drug: Tacrolimus;   Biological: Sargramostim;   Biological: Filgrastim;   Drug: Antithymocyte Globulin (Rabbit)
Sponsors:   Virginia Commonwealth University;   Massey Cancer Center
Recruiting - verified November 2016

Diabetes Islet Preservation Immune Treatment

Conditions:   Diabetes Mellitus, Type 1;   Hypoglycemia;   Autoimmune Diseases;   Diabetes Mellitus
Interventions:   Drug: Anti-Thymocyte Globulin (ATG);   Drug: Placebo;   Drug: Pegylated GCSF;   Drug: Interleukin 2;   Drug: Etanercept;   Drug: Exenatide
Sponsors:   Camillo Ricordi and Jay Skyler;   Diabetes Research Institute Foundation
Not yet recruiting - verified November 2016

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Condition:   Epidermolysis Bullosa
Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified February 2017

Answer ALS: Individualized Initiative for ALS Discovery

Conditions:   Amyotrophic Lateral Sclerosis;   Primary Lateral Sclerosis;   Flail Arm ALS;   Progressive Muscular Atrophy;   Monomelic Amyotrophy;   Motor Neuron Disease;   Asymptomatic ALS Gene Carriers
Intervention:  
Sponsors:   Johns Hopkins University;   Massachusetts General Hospital;   Emory University;   Ohio State University;   Washington University School of Medicine;   Cedars-Sinai Medical Center;   University of California, Irvine;   Massachusetts Institute of Technology;   New York Genome Center;   Leandro P. Rizzuto Foundation